Alzamend Neuro 2025 Financial Results & Clinical Program Updates
Alzamend Neuro, a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, reported positive...
Novel Genetic Evidence Confirms ADH1 Prevalence & Underdiagnosis
An analysis of genetic and health data from over 700,000 individuals confirms previous estimates of Autosomal Dominant Hypocalcemia type...
Dr. Iwasaki Joins Spear Study on Long COVID Antibodies
Invivyd has appointed Dr. Akiko Iwasaki, a renowned immunobiologist from Yale School of Medicine, to its SPEAR Study Group....
Scancell’s Phase 2 Data Shows Improved Outcomes in Late-Stage Melanoma
Scancell Holdings plc announced positive Phase 2 SCOPE trial data for its SCIB1/iSCIB1+ Immunobody® DNA active immunotherapies combined with...
Quelimmune Shows Promise in Pediatric Acute Kidney Injury
SeaStar Medical announced positive preliminary results from its SAVE Surveillance Registry for its QUELIMMUNE therapy in critically ill pediatric...
Obefazimod Shows Positive Phase 3 Results in Ulcerative Colitis Trials
Abivax reported positive Phase 3 results for obefazimod, a first-in-class oral miR-124 enhancer, in two induction trials for moderate...
Bio-Hermes Study: Transforming Alzheimer’s Research
IXICO, a neuroscience imaging and biomarker analytics company, has joined the Bio-Hermes-002 study, a collaborative effort aimed at improving...
First Patient Dosed in Tamarind Trial for MDD
HMNC Brain Health and Spruce Biosciences have dosed the first patient in the Phase 2 TAMARIND clinical trial. This...
Study: Perimenopause Most Misunderstood Health Transition
Bonafide Health’s fifth annual State of Menopause Study reveals that women aged 40-49 are significantly impacted by perimenopause, experiencing...
LifeVantage Announces Expanded Human Clinical Study, 200% GLP-1 Surge
LifeVantage Corporation announced positive results from a combined analysis of two clinical trials on its MindBody GLP-1 System, a...